Last reviewed 2026-04-22 · How we verify

Treatment F

Treatment F is not a recognized pharmaceutical product identifier in standard drug databases.

At a glance

Mechanism of action

Without a brand name, generic name, or specific molecular target provided, this appears to be either a placeholder designation or an internal research code. Standard pharmaceutical nomenclature and regulatory databases do not contain a marketed drug identified solely as 'Treatment F' from Merck Sharp & Dohme LLC.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors (PHASE2)
• Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
• A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
• Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.